These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J. Thromb Haemost; 1993 Feb 01; 69(2):157-63. PubMed ID: 8456428 [Abstract] [Full Text] [Related]
3. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Chamberlin JR, Lewis B, Leya F, Wallis D, Messmore H, Hoppensteadt D, Walenga JM, Moran S, Fareed J, McKiernan T. Can J Cardiol; 1995 Jun 01; 11(6):511-4. PubMed ID: 7780873 [Abstract] [Full Text] [Related]
4. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E. Am J Cardiol; 1993 Apr 01; 71(10):778-82. PubMed ID: 8456753 [Abstract] [Full Text] [Related]
8. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Fuchs J, Cannon CP. Circulation; 1995 Aug 15; 92(4):727-33. PubMed ID: 7641350 [Abstract] [Full Text] [Related]
10. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model. Deschênes I, Finkle CD, Winocour PD. Thromb Haemost; 1998 Jul 15; 80(1):186-91. PubMed ID: 9684808 [Abstract] [Full Text] [Related]
12. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Soria J, Soria C, Camez A, Mirshahi MC, Bassand JP. Thromb Haemost; 1994 May 15; 71(5):558-62. PubMed ID: 8091380 [Abstract] [Full Text] [Related]
13. Hirulog therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Reid T, Alving BM. Am J Hematol; 1994 Apr 15; 45(4):352-3. PubMed ID: 8192819 [No Abstract] [Full Text] [Related]
14. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Sharma GV, Lapsley D, Vita JA, Sharma S, Coccio E, Adelman B, Loscalzo J. Am J Cardiol; 1993 Dec 15; 72(18):1357-60. PubMed ID: 8256726 [Abstract] [Full Text] [Related]
15. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Théroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A. Eur Heart J; 2000 Sep 15; 21(17):1473-81. PubMed ID: 10952840 [Abstract] [Full Text] [Related]
16. Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model. Hamelink JK, Tang DB, Barr CF, Jackson MR, Reid TJ, Gomez ER, Alving BM. J Vasc Surg; 1995 Mar 15; 21(3):492-8. PubMed ID: 7877232 [Abstract] [Full Text] [Related]
17. Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. Muller DW, Gordon D, Topol EJ, Levy RJ, Golomb G. Am Heart J; 1996 Feb 15; 131(2):211-8. PubMed ID: 8579010 [Abstract] [Full Text] [Related]